Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017140831) ANTIBODIES FOR IL-17C
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

Claims

1 . An antibody or antibody fragment specific for IL-17C wherein said antibody or antibody fragment cross-competes with an antibody comprising

(a) the HCDR1 region of SEQ ID No.. 7, the HCDR2 region of SEQ ID No.: 8, the HCDR3 region of SEQ ID No.: 9, the LCDR1 region of SEQ ID No.: 13, the LCDR2 region of SEQ ID No.: 14 and the LCDR3 region of SEQ ID No.: 15, or

(b) the HCDR1 region of SEQ ID No.: 20, the HCDR2 region of SEQ ID No.: 21 , the HCDR3 region of SEQ ID No.: 22, the LCDR1 region of SEQ ID No.: 26, the LCDR2 region of SEQ ID No.: 27 and the LCDR3 region of SEQ ID No.: 28.

2. An antibody or antibody fragment specific for IL-17C wherein said antibody or antibody fragment comprises

(a) a HCDR1 region comprising the amino acid sequence of SEQ ID No.: 7, a HCDR2 region comprising the amino acid sequence of SEQ ID No.: 8, a HCDR3 region comprising the amino acid sequence of SEQ ID No.: 9, a LCDR1 region comprising the amino acid sequence of SEQ ID No.: 13, a LCDR2 region comprising the amino acid sequence of SEQ ID No.: 14 and a LCDR3 region comprising the amino acid sequence of SEQ ID No.: 15, or

(b) a HCDR1 region comprising the amino acid sequence of SEQ ID No.: 20, a HCDR2 region comprising the amino acid sequence of SEQ ID No.: 21 , a HCDR3 region comprising the amino acid sequence of SEQ ID No.: 22, a LCDR1 region comprising the amino acid sequence of SEQ ID No.: 26, a LCDR2 region comprising the amino acid sequence of SEQ ID No.: 27 and a LCDR3 region comprising the amino acid sequence of SEQ ID No.: 28.

3. An antibody or antibody fragment according to claim 2 wherein said antibody or antibody fragment comprises

(a) a HCDR1 region of SEQ ID No : 7, the HCDR2 region of SEQ ID No.: 8, the HCDR3 region of SEQ ID No.: 9, the LCDR1 region of SEQ ID No.: 13, the LCDR2 region of SEQ ID No.: 14 and the LCDR3 region of SEQ ID No.: 15, or

(b) a HCDR1 region of SEQ ID No.: 20, the HCDR2 region of SEQ ID No. : 21 , the HCDR3 region of SEQ ID No.: 22, the LCDR1 region of SEQ ID No.: 26, the LCDR2 region of SEQ ID No.: 27 and the LCDR3 region of SEQ ID No.: 28.

4. An antibody or antibody fragment according to one of the preceding claims, wherein said antibody or antibody fragment is specific for human IL-17C.

5. An isolated antibody or antibody fragment according to claim 4, wherein said antibody or antibody fragment is specific for human IL-17C, cynomolgus IL-17C and mouse IL-17C.

6. The antibody or antibody fragment according to one of the preceding claims, wherein said antibody or antibody fragment is a human, humanized or chimeric antibody or antibody fragment.

7. An antibody or antibody fragment according to one of the preceding claims, wherein said antibody or antibody fragment comprises a heavy chain of SEQ ID No.: 17 and a Sight chain of SEQ ID No.: 16.

8. An antibody or antibody fragment according to one of the claims 1 -7, wherein said antibody or antibody fragment comprises a heavy chain of SEQ ID No.: 30 and a light chain of SEQ ID No.: 29.

9. An antibody or antibody fragment according to one of the preceding claims, wherein said antibody or antibody fragment is an isolated antibody or antibody fragment.

10. An antibody or antibody fragment according to one of the preceding claims, wherein said antibody or antibody fragment is a recombinant antibody or antibody fragment.

1 1. An antibody or antibody fragment according to one of the preceding claims for use in the treatment of a subject in need thereof.

12. A nucleic acid composition comprising a nucleic acid sequence or a plurality of nucleic acid sequences encoding the antibody or antibody fragment according to any one of claims 1 to 1 1 .

13. A vector composition comprising a vector or a plurality of vectors comprising the nucleic acid sequence or plurality of nucleic acid sequences of claim 12.

14. A cell comprising the vector composition of claim 13.

15. A pharmaceutical composition comprising the antibody or antibody fragment according to one of the claims 1 to 1 1 and a pharmaceutically acceptable carrier or excipient.